An indirect ELISA kit for detecting avian reovirus antibodies
By constructing and using Sigma-B protein antigen peptides and nucleic acid molecules, an ELISA kit that can detect avian reovirus antibodies was established, which solved the problem of difficulty in detecting ARV antibodies in the prior art and achieved high accuracy and specificity detection effect.
Patent Information
- Application Number
- CN202311481727.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-11-09
AI Technical Summary
The prior art is difficult to effectively detect avian reovirus (ARV) antibodies, especially when the agar diffusion assay cannot detect antibodies with too low titers, and the PCR method is limited due to the high sequence diversity of different ARV isolates. The detection effect leads to difficulties in clinical diagnosis and vaccine testing.
By analyzing Sigma-B protein sequence information, constructing antigen recombinant epitope, constructing nucleic acid molecules and purifying protein standards for use in ELISA enzyme plates, and establishing methods that can detect ARV antibodies, including constructing Sigma-B protein antigen peptides and Nucleic acid molecules are prepared to detect antibodies to avian reovirus, and the S/P value is used for detection.
The specific identification of ARV infection and vaccine immunity was achieved, which improved the accuracy and sensitivity of the detection, and had low cross-reaction with other pathogens, with high specificity and compliance rates.
Smart Images

Figure GDA0005075162710000041 
Figure GDA0005075162710000051 
Figure GDA0005075162710000052
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology detection, and specifically relates to an indirect ELISA antibody detection kit for detecting avian reovirus. Background Art
[0002] Avian reovirus (ARV) is a member of the Reoviridae family and the Orthoreovirus genus. Infection with this virus can cause a variety of diseases in poultry, mainly viral arthritis, dwarf syndrome, respiratory diseases, intestinal diseases, pericarditis, enteritis, hepatitis, bursa of Fabricius and thymic atrophy, among which viral arthritis / tenosynovitis is the main feature. Natural infection is more common at 4 to 7 weeks of age. Infected chickens are depressed, like to lie down and are tired, with swollen tarsal joints, and severe cases show lameness. In addition, infection with this virus occurs not only in broilers, but also occasionally in laying hens. One-day-old chicks are most susceptible to the virus, and the mortality rate after infection can reach 2% to 9%, and the morbidity rate is 5% to 60%, or even 100%. Avian reovirus is prevalent in chickens, turkeys, ducks, parrots and other poultry, and can be transmitted horizontally or vertically through eggs. Reovirus can also exacerbate diseases caused by other pathogens, such as chicken anemia factor, Escherichia coli and Newcastle disease virus. Due to infection with reovirus, the body's immune function is reduced, resulting in increased susceptibility to other infectious causes.
[0003] ARV has a typical reovirus morphology. The virus particles are icosahedral symmetric, without envelope, and have a double-layer nucleocapsid structure with an external diameter of about 75nm. The viral genome is double-stranded RNA, divided into 10 gene segments, with a size of about 23Kb. The proteins encoded by the genome include 10 structural proteins and 4 non-structural proteins. Among them, the Sigma-A protein encoded by the S2 gene contains 416 amino acids and is the main component of the virus's inner shell structure. The Sigma-A protein participates in the anti-interferon process of ARV and can assist ARV in responding to the host's immune defense mechanism. It has been reported that the Sigma-A protein has nucleotide pyrophosphohydrolase activity, which can provide energy for the transcription and replication process of ARV. The Sigma-A protein has ssRNA binding activity; the Sigma-B protein encoded by the S3 gene contains 367 amino acids and is the main component of the ARV capsid protein. The Sigma-B protein binds to the μB and μBC proteins in the cytoplasm of infected cells to form a multimeric complex. Sigma-B protein is related to the pathogenic mechanism of ARV and can enhance the infection ability of ARV with the help of Sigma-C protein; the Sigma-C protein encoded by the third ORF on the S1 gene contains 326 amino acids and is a structural protein with the smallest molecular weight but plays an important role in viral infection. Sigma-C protein participates in the adsorption process of ARV and can mediate the binding of the virus to specific receptors; Sigma-C protein can induce cells to form syncytia and present typical CPE of ARV; in addition, Sigma-C protein has surface antigens of type-specific neutralization reaction and can stimulate the host to secrete neutralizing antibodies, among which Sigma-B has group-specific antigens and Sigma-C has type-specific antigens.
[0004] ARV infection is generally diagnosed based on epidemiological surveys, clinical symptoms, and pathological changes. Since ARV is prone to secondary mixed infection with a variety of pathogenic microorganisms, it needs to be further identified through laboratory means, including pathogen isolation and identification, agar diffusion test, virus neutralization test, fluorescent antibody test, enzyme-linked immunosorbent assay and other molecular biology and serological detection methods. However, ARV spreads rapidly, and the agar diffusion test cannot detect antibodies with too low titers. In terms of molecular biological diagnostic technology, different ARV isolates have high sequence diversity, which to a certain extent limits the detection effect of the PCR method. Therefore, the establishment of a broad-spectrum serological diagnostic method is an urgent need for clinical diagnosis, vaccine testing, and epidemiological research. Summary of the invention
[0005] The present invention analyzes the secondary structure, hydrophilicity, antigenicity and the like by analyzing the sequence information of Sigma-B protein, selects antigen recombinant epitopes, constructs them into prokaryotic expression vectors, purifies and prepares protein standards, and coats them onto ELISA enzyme-labeled plates for detecting poultry serum, thereby establishing an ELISA method capable of detecting ARV antibodies, so as to achieve the purpose of specifically identifying ARV infection and vaccine immunity.
[0006] In a first aspect, the present invention provides an avian reovirus Sigma-B protein antigen peptide, the amino acid sequence of the Sigma-B protein antigen peptide is shown in SEQ ID NO.1;
[0007] DGNYFPHHKCHQQQFRTDTPLLRYVRIGRTTEHLLDQYAVALESIADHYDEISQRMVDEPESDEVAPLDIVTRTESIRSDKAVDPDFWTYPLERRSDDSRRDIASACWRMIDASSRSLTLPNCLVSPSLHSRSVFGQMQTTTTIYDVA ASGKAVKFSPMVATSQRDAGPVMLANADPAEGVYSFWTSHFAFSPLIGGVGITGQYARESYHQVGHPVIGSGKKASHYRNLFMESWRGWSKSAFAYATGMEPAECESRLRGHARTMLGRSLPHVCDDEVAQQSGAVLTSLQKTNKF.
[0008] Furthermore, the avian reovirus Sigma-B protein antigen peptide also includes a polypeptide containing 80%-100% homologous sequence.
[0009] In a second aspect, the present invention provides a construct comprising a nucleic acid molecule of the avian reovirus Sigma-B protein antigenic peptide described in the first aspect.
[0010] Furthermore, the nucleic acid molecule encodes the nucleic acid molecule of the avian reovirus Sigma-B protein antigen peptide as described in the first aspect of the present invention.
[0011] In a third aspect, the present invention provides a kit for detecting antibodies to avian reovirus, the kit comprising the Sigma-B protein antigen peptide described in the first aspect of the present invention.
[0012] Furthermore, the kit for detecting avian reovirus antibodies also contains enzyme-labeled secondary antibodies, washing solution, sample diluent, stop solution, etc.
[0013] Furthermore, the sample diluent and washing solution are phosphate buffered saline (PBS).
[0014] Furthermore, the antibody detection kit also includes a PVC base plate, a gold label pad, a sample pad and a water absorbent pad.
[0015] In a fourth aspect, the present invention provides an application of a Sigma-B protein antigen peptide in the preparation of a kit for detecting avian reovirus antibodies, wherein the application is achieved by measuring the S / P value of the test poultry serum.
[0016] Further, the S / P value = (clinical sample OD 450nm Value - negative control serum OD 450nm Mean) / (positive control serum OD 450nm Mean - negative control serum OD 450nm mean).
[0017] Furthermore, when the S / P value of the test poultry serum is ≥0.35, it is judged as positive; when the S / P value of the test poultry serum is <0.35, it is judged as negative. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Protein small-scale expression diagram;
[0019] Figure 2 Protein expression detection diagram;
[0020] Figure 3 Protein purification diagram. DETAILED DESCRIPTION
[0021] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention.
[0022] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0023] Example 1 Construction of recombinant expression plasmid and protein purification
[0024] 1. Construction of recombinant expression plasmid
[0025] The sequence SEQ ID NO.1 of the present invention and the plasmid pET-30a were double-digested with restriction endonucleases EcoRⅠ and Xho I, respectively. The purified and recovered fragments and the digested products of the expression vector were connected with a DNA Ligation Kit and then transformed into competent cells (BL21).
[0026] 2. Small-scale expression of recombinant proteins
[0027] The clones identified as positive by PCR were picked and placed in 1.5 mL of LB liquid medium containing kanamycin resistance, and cultured at 37°C, 200 r / min; cultured until OD = 0.6-0.8, induced by IPTG (0.5 mM), cultured at 37°C, 200 r / min for 2 h; 1 mL of induced bacterial solution was taken, centrifuged at 12000 rpm for 1 min, the supernatant was discarded, and the precipitate was blown off with 50-100 μL Tris-HCl (pH 8.0) solution (the amount of buffer added depends on the amount of bacteria), and 2× loading buffer with the same volume as the buffer was added, and electrophoresis was performed at 100°C for 5 min. The results showed that a specific target band of the recombinant Sigma-B protein appeared at a size of about 43 KD ( Figure 1 ), indicating that Sigma-B protein was successfully expressed.
[0028] 3. Large-scale expression and purification of recombinant proteins
[0029] Transfer the cultured bacterial suspension to 500mL of the corresponding resistance LB liquid medium at a ratio of 1:50, shake at 37℃, 200r / min, culture until OD=0.6-0.8, induce with IPTG (0.5mM) at 37℃ for 3h; harvest bacteria: centrifuge at 8000rpm for 6min. Discard the supernatant; ultrasonic bacterial disruption: blow away the bacteria with 20-30ml 10mM Tris-HCl (pH 8.0) solution, ultrasonically disrupt (500W, 70 times, 5s each time, 5s interval); determine the expression form by electrophoresis: take 100μL of the bacterial suspension after ultrasonication, centrifuge at 12000r / min for 10min, take 50μL of the supernatant to another EP tube, discard the supernatant and blow away the precipitate with 50μL 10 mM Tris-HCl (pH 8.0) solution. The supernatant and precipitate were taken for SDS-PAGE detection, and a large amount of target protein was detected in the precipitate, indicating that the expression form of the recombinant bacteria was inclusion body expression ( Figure 2). The expressed protein was purified as follows: the precipitate obtained by ultrasonic disruption of the bacteria was resuspended with 10mM Tris (pH8.0), 10000rpm, 4℃, 15min. Then 20mL 2M urea + 10mMTris was added, mixed, 10000rpm, 4℃, 15min to wash the precipitate. 10mL 8M urea + 10mM Tris + 0.5M NaCl was used to dissolve the precipitate, mixed, ultrasonicated for 2-3min, 10000rpm, 4℃, 15min, and the supernatant was collected to obtain the crude protein. The crude protein was purified by nickel column, firstly, 40mL of 10mM Tris-HCl (pH8.0) solution of 15mM imidazole + 8M urea + 0.5M sodium chloride was used to elute the impurities. Secondly, 40mL of 10mM Tris-HCl (pH8.0) solution of 60mM imidazole + 8M urea + 0.5M sodium chloride was used to elute the impurities. Finally, 40 mL of 10 mM Tris-HCl (pH 8.0) solution containing 300 mM imidazole + 8 M urea + 0.5 M sodium chloride was used to elute the target protein. When the reading rose to 10, protein peaks were collected. 50 μL of sample was taken for SDS-PAGE electrophoresis detection ( Figure 3 ). The BCA method was used for quantification, and the concentration of the purified protein was 0.5 mg / mL, with a purity better than 85%, and was named ARV-Sigma-B.
[0030] Example 2 Determination of optimal process parameters
[0031] 1. Determination of the optimal working concentration of antigen and antibody
[0032] The purified Sigma-B recombinant protein was diluted with coating solution to concentrations of 0.5μg / ml, 1.0μg / ml, 1.5μg / ml, 2.0μg / ml, and 2.5μg / ml, and added to the ELISA plate from left to right, 100μl / well, and incubated overnight at 4°C; the next day, washed three times with PBST, 5 min each time; and blocked with 5% skim milk 200μl / well at 37°C for 2h. The standard positive and negative serum was diluted in a gradient of 1:100, 1:200, 1:400, and 1:800, 100μl / well, added to the ELISA plate from top to bottom, incubated at 37℃ for 1h, washed 3 times, 5min each time; added 1:20000 enzyme-labeled secondary antibody, incubated at 37℃ for 1h, washed 3 times, 5min each time, and patted dry; added 100μl TMB colorimetric solution to each well, incubated at 37℃ in the dark for 10min; added 50μl stop solution to terminate the reaction, and immediately used an ELISA reader to measure the OD450nm value. The optimal working concentration of the antigen and antibody was determined based on the OD450nm value and P / N value. The results showed that when the antigen coating concentration was 2.0μg / ml and the antibody dilution was 1:400, the OD450nm value of the positive serum was close to 1.0, and the P / N value was the largest. Therefore, the optimal coating concentration of ELISA antigen was determined to be 2.0 μg / ml, and the optimal serum dilution was determined to be 1:400. The results are shown in Tables 1 and 2.
[0033] Table 1 Optimal working concentration test results of antigen and antibody (OD 450nm value)
[0034]
[0035]
[0036] Table 2 Optimal working concentration test results of antigen and antibody (P / N value)
[0037]
[0038] 2. Determination of the optimal dilution of enzyme-labeled secondary antibody
[0039] The ELISA plate was coated with the antigen at the optimal concentration, the positive and negative serum was diluted at the optimal dilution, the enzyme-labeled secondary antibody was diluted at 1:5000, 1:10000, 1:20000, 1:40000, and each dilution was repeated three times. The optimal working concentration of the enzyme-labeled secondary antibody was determined by the OD450nm value and the P / N value. The results showed that when the concentration of the enzyme-labeled secondary antibody was 1:20000, the P / N value was the largest, and the results are shown in Tables 3 and 4.
[0040] Table 3 Optimal dilution test results of enzyme-labeled secondary antibody (OD450nm value)
[0041]
[0042] Table 4 Optimal dilution test results of enzyme-labeled secondary antibody (P / N value)
[0043]
[0044] 3. Determination of the optimal coating time
[0045] The ELISA plate was coated with the antigen at the optimal concentration, and three coating conditions were set: incubation at 37℃ for 1h, coating at 4℃ overnight; incubation at 37℃ for 3h, coating at 4℃ overnight; coating at 4℃ overnight, with 4 replicates for each coating condition. The negative and positive sera and enzyme-labeled secondary antibodies were diluted at the optimal dilution, and the optimal coating time of the antigen was determined by the OD450nm value and P / N value. The results showed that the optimal coating condition was coating at 4℃ overnight, as shown in Tables 5 and 6.
[0046] Table 5 Optimal coating conditions test results (OD450nm value)
[0047]
[0048] Table 6 Optimal coating conditions test results (P / N value)
[0049]
[0050] 4. Selection of the best blocking solution
[0051] The ELISA plate was coated with the antigen at the optimal concentration, and the plate was coated overnight at 4°C. After washing, 5% skim milk powder, 5% skim milk powder + ELISA plate stabilizer, 3% gelatin, 3% gelatin + ELISA plate stabilizer, 1% BSA, 1% BSA + ELISA plate stabilizer, and ELISA plate stabilizer were used respectively. Each well was repeated three times, and the negative and positive serum and enzyme-labeled secondary antibody were diluted at the optimal dilution. The optimal blocking solution was determined by the OD450nm value and the P / N value. The results showed that when blocked with 5% skim milk powder, the P / N value was the largest, so 5% skim milk powder was selected as the optimal blocking solution. The results are shown in Tables 7 and 8.
[0052] Table 7 Determination of the best blocking solution (OD450nm value)
[0053]
[0054] Table 8 Determination of the best blocking solution (P / N value)
[0055]
[0056] 5. Determination of closure time
[0057] The ELISA plate was coated with the optimal concentration of antigen at 4°C overnight. After washing, it was blocked with 5% skim milk powder for 30 minutes, 60 minutes, 90 minutes, and 120 minutes, and 3 replicates were set for each condition. The optimal blocking solution was determined by the OD450nm value and the P / N value. The results showed that the optimal blocking time was 120 minutes. The results are shown in Tables 9 and 10.
[0058] Table 9 Determination of blocking time (OD450nm value)
[0059]
[0060] Table 10 Determination of closure time (P / N value)
[0061]
[0062]
[0063] 6. Determination of the optimal reaction time of serum and enzyme-labeled secondary antibody
[0064] Dilute the negative and positive serum and enzyme-labeled secondary antibody at the optimal dilution, incubate for 30min, 45min, 60min, and 90min respectively, and set 3 replicates for each gradient to explore the optimal serum and enzyme-labeled secondary antibody incubation time. The optimal reaction time of serum and enzyme-labeled secondary antibody was determined by OD450nm value and P / N value. The results showed that the optimal serum incubation time was 60min, and the optimal secondary antibody incubation time was 60min. The results are shown in Tables 11 and 12.
[0065] Table 11 Determination of the optimal reaction time of serum and enzyme-labeled secondary antibody (OD450nm value)
[0066]
[0067] Table 12 Determination of the optimal reaction time of serum and enzyme-labeled secondary antibody (P / N value)
[0068]
[0069]
[0070] 7. Determination of color development time
[0071] Add color developing solution and incubate at 37°C in the dark for 3min, 5min, 10min, 15min, and 20min, respectively. Set 3 replicates for each color developing time for positive and negative serum. Determine the optimal color developing time by OD450nm value and P / N value. The results show that when the reaction time is 10min, the P / N value is the largest, so the optimal color developing time of the substrate is 10min. The results are shown in Tables 13 and 14.
[0072] Table 13 Determination of color development time (OD450nm value)
[0073]
[0074] Table 14 Determination of color development time (P / N value)
[0075]
[0076] Example 3 Indirect ELISA kit for detecting avian reovirus
[0077] The indirect ELISA kit for detecting reovirus of the present invention is prepared by the following steps:
[0078] (1) Coating: Coat the ELISA plate with recombinant Sigma-B protein. The optimal coating concentration of Sigma-B is 2.0 μg / ml. 100 μl / well. Incubate overnight at 4°C. Wash three times with PBST buffer the next day for 5 min each time and pat dry.
[0079] (2) Blocking: Add 5% skim milk powder, 100 μl / well, block at 37°C for 2 h, wash 3 times, 5 min each time, and pat dry;
[0080] (3) Serum incubation: Add 1:400 diluted serum to be tested, incubate at 37°C for 60 min, wash three times, 5 min each time, and pat dry;
[0081] (4) Secondary antibody incubation: add 1:20,000 enzyme-labeled secondary antibody, incubate at 37°C for 60 min, wash three times, 5 min each time, and pat dry;
[0082] (5) Color development: Add 100 μl / well of TMB color development solution and incubate at 37°C in the dark for 10 min;
[0083] (6) Stop: Add stop solution 2M H2SO4, 50ul / well;
[0084] (7) Reading: Read OD using an ELISA reader 450nm value.
[0085] Example 4 Effect verification of avian reovirus indirect ELISA kit
[0086] The critical value of this kit is determined by using the established indirect ELISA antibody detection method for avian reovirus to test negative samples respectively, and according to the OD of clinical negative serum samples 450nm The S / P value of each sample (N01-N92 are avian reovirus negative serum) was calculated based on the test results. S / P value = (Clinical sample OD 450nm Value - negative control serum OD 450nmMean) / (positive control serum OD 450nm Mean - negative control serum OD 450nm Mean) (Table 15), using the mean + 3 times standard deviation method, the test results were analyzed to obtain the critical value, and the calculated critical value was 0.3466, which was rounded to two decimal places as 0.35. In order to verify the determined critical value, we tested 30 positive samples (P1 to P30 were sera positive for avian reovirus antibodies) and used the determined critical value to judge the results, all of which were positive (Table 16). Based on the above test results, we will determine the critical value of the avian reovirus indirect ELISA antibody detection method to be 0.35, that is, S / P ≥ 0.35 is judged as positive, and S / P < 0.35 is judged as negative.
[0087] Table 15 Results of indirect ELISA antibody detection method for avian reovirus in clinical negative serum samples
[0088]
[0089]
[0090] Table 16 Detection results of avian reovirus indirect ELISA antibody detection method for positive samples
[0091]
[0092]
[0093] 1. Specificity experiment of indirect ELISA
[0094] The established indirect ELISA method was used to detect the positive serum of known pathogens such as chicken egg drop syndrome virus (EDSV), avian leukosis virus, infectious laryngotracheitis virus, and avian orthoreovirus, and ARV positive serum and negative serum controls were set up at the same time. The commercial kit was used as a control to determine whether there was a cross reaction and analyze the specificity of this indirect ELISA kit. The results showed (Table 17) that the S / P values were all less than 0.35, which was judged to be negative, indicating that the Sigma-B protein had no cross reaction with the positive serum of the above viruses, and the indirect ELISA kit had good specificity.
[0095] Table 17 Specificity test results of indirect ELISA antibody test method for avian reovirus
[0096]
[0097] 2. Determination of the compliance rate of indirect ELISA
[0098] The indirect ELISA kit of the present invention was used to detect 154 clinical serum samples, and compared with commercial kits, the sensitivity, specificity and coincidence rate of the kit were analyzed.
[0099] Relative sensitivity (%) = number of positives / (number of positives + number of false negatives) × 100%
[0100] Relative specificity (%) = number of negatives / (number of negatives + number of false positives) × 100%
[0101] Total compliance rate (%) = (positive number + negative number) / total number of tests × 100%
[0102] The results show that the indirect ELISA kit of the present invention detects 154 clinical sera, of which 126 are negative samples and 28 are positive samples. The commercial kit detects 154 clinical sera, of which 29 are positive samples and 125 are negative samples (Table 18). It can be seen that the relative sensitivity of the indirect ELISA method of the present invention is 93.10%, the relative specificity is 99.20%, and the total compliance rate is 98.05% (Table 19).
[0103] Therefore, it can be seen that the indirect ELISA kit of the present invention has higher sensitivity and specificity, and has a higher compliance rate compared with existing commercial kits.
[0104] Table 18 Avian reovirus indirect ELISA antibody detection method and commercial kit test results
[0105]
[0106]
[0107]
[0108] Table 19 Sample test results compliance rate
[0109]
Claims
1. An avian reovirus Sigma-B protein antigen peptide, the amino acid sequence of the Sigma-B protein antigen peptide is shown in SEQ ID NO.1: DGNYFPHHKCHQQQFRTDTPLLRYVRIGRTTEHLLDQYAVALESIADHYDEISQRMVDEPESDEVAPLDIVTRTESIRSDKAVDPDFWTYPLERRSDDSRRDIASACWRMIDASSRSLTLPNCLVSPSLHSRSVFGQMQTTTTIYDVA ASGKAVKFSPMVATSQRDAGPVMLANADPAEGVYSFWTSHFAFSPLIGGVGITGQYARESYHQVGHPVIGSGKKASHYRNLFMESWRGWSKSAFAYATGMEPAECESRLRGHARTMLGRSLPHVCDDEVAQQSGAVLTSLQKTNKF.
2. A construct comprising a nucleic acid molecule encoding the avian reovirus Sigma-B protein antigenic peptide as described in claim 1.
3. A kit for detecting avian reovirus antibodies, the kit comprising the Sigma-B protein antigen peptide as claimed in claim 1.
4. The kit for detecting avian reovirus antibodies according to claim 3, characterized in that: The kit for detecting avian reovirus antibodies also contains enzyme-labeled secondary antibodies, washing liquid, sample diluent, and stop solution.
5. The kit for detecting avian reovirus antibodies according to claim 3, characterized in that: The antibody detection kit also includes a PVC bottom plate, a gold label pad, a sample pad and a water absorbent pad.
6. Use of the Sigma-B protein antigen peptide as claimed in claim 1 in the preparation of a kit for detecting avian reovirus antibodies, wherein the use is achieved by measuring the S / P value of the test poultry serum.
